Cencora reported fiscal Q4 2026 sales of US$88.35b and net income of US$519.4m, with full year earnings rising to US$3.48b, and increased its quarterly dividend to US$0.66 per share payable on 30 November 2026. The sharp shift from a prior year quarterly net loss to profit, combined with a higher dividend and new segment reporting, gives investors clearer visibility into how specialty services and acquisitions such as OneOncology contribute to Cencora's earnings profile. Next, the focus...
CONSHOHOCKEN, Pa., November 04, 2026--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility.
Cencora (NYSE: COR) agreed to acquire American Oncology Network to expand its community-based cancer care footprint. The deal broadens Cencora's physician practice management services into 12 additional states through American Oncology Network's clinic footprint. American Oncology Network brings a network of oncology practices that operates primarily in community settings across the United States. Cencora's purchase of American Oncology Network reshapes its reach in community oncology, but...
Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Detailed price information for Cencora Inc (COR-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.